Holen Sie sich die Stockscreener-App
13.85
1.02%
0.14
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
PMN Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ove - GuruFocus
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High? - Yahoo Finance
ProMIS Neurosciences Inc (PMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to revenue forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
ProMIS Neurosciences Inc. Actuals & Estimates (NASDAQ:PMN) - TradingView
PMN Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to sales forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to book forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
H.C. Wainwright reiterates ProMIS Neurosciences stock rating at buy By Investing.com - Investing.com Nigeria
ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProMIS Neurosciences Inc (PMN) Institutional Confidence - TradingKey
ProMIS Neurosciences Inc (PMN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ProMIS Neurosciences Inc (PMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProMIS Neurosciences Inc (PMN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PMN Q1 2026 Earnings: EPS Beat Surprises as ProMIS Advances PipelinePretax Income Report - newsline.com
PMN Q1 2026 Earnings: Narrowing Losses Amidst Clinical ProgressProfit Inflection Point - newsline.com
ProMIS Neurosciences (PMN) Dips 3.54% as Biotech Stock Tests Key Support ZonePrice Action Signals - newsline.com
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet - Yahoo Finance
ProMIS Neurosciences Inc. (PMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancesAnalyst Drop Coverage - newsline.com
H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com - Investing.com Canada
H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
PMN Q1 2026 Earnings: Narrower-than-Expected Loss Amid Ongoing Clinical DevelopmentROA Comparison - newsline.com
ProMIS Neurosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
PMN Q1 2026 Earnings: EPS Surprises to the Upside Despite Lack of RevenueMargin Guidance - newsline.com
PMN Q1 2026 Earnings: EPS Surprises Positively Amid Continued R&D ProgressShort-Term Outlook - newsline.com
ProMIS Neurosciences (PMN) Faces Bearish Pressure as Shares Slide 3.70%Fibonacci Entry Signals - newsline.com
ProMIS Neurosciences (PMN) Holds Steady Near Support as Biotech Sector Watches Key LevelsSynthetic Short - newsline.com
ProMIS Neurosciences to Participate in Upcoming Conferences in June - The Manila Times
Alzheimer’s drug trial data from ProMIS expected in early Q3 2026 - Stock Titan
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
PMNProMIS Neurosciences Inc Stock Price and Quote - Finviz
ProMIS Neurosciences (PMN) Slips 5.65% as Shares Test Key Support LevelWave Alternation - newsline.com
PMN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Neurodegenerative PipelineRevenue Breakdown Analysis - The Legal Advocate
PMN Q1 2026 Earnings: Narrower-than-expected Loss; Stock Gains on Pipeline ProgressPretax Income Report - Newser
Yu Fan's ProMIS Neurosciences Inc(PMN) Holding History - GuruFocus
ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price - Stock Titan
ProMIS Neurosciences (PMN) director granted options on 16,500 shares - Stock Titan
ProMIS Neurosciences (PMN) CEO awarded 160,000 options at $10.77 strike - Stock Titan
ProMIS Neurosciences (PMN) director awarded long-dated stock options - Stock Titan
ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years - Stock Titan
Executive at ProMIS (PMN) receives 18,167 stock options expiring 2036 - Stock Titan
ProMIS Neurosciences (PMN) director receives 16,500 stock options grant - Stock Titan
ProMIS Neurosciences (PMN) CDO awarded 50,000 stock options - Stock Titan
Director at ProMIS Neurosciences (PMN) receives new option grants as board compensation - Stock Titan
PMN Q1 2026 Earnings: Narrowed EPS Surprise Drives Positive Stock ReactionDividend Earnings Report - The Legal Advocate
ProMIS Neurosciences | 4: Statement of changes in beneficial ownership of securities-Director Alex Slanix Paul - Moomoo
ProMIS Neurosciences (NASDAQ: PMN) shareholders approve larger 2025 stock option plan - Stock Titan
Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH) - The Globe and Mail
Great Point, Dr. Jay and Nordahl report 9.99% stake in PROMIS (PMN) - Stock Titan
Wellington Group discloses 895,871-share holding in ProMIS (PMN) - Stock Titan
1.16%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):